Evidence map›Paper›PMID 31728622›Full record

ArticleRadiation and environmental biophysics2020

MnTnBuOE-2-PyP treatment protects from radioactive iodine (I-131) treatment-related side effects in thyroid cancer.

Anery Patel, Elizabeth A Kosmacek, Kurt W Fisher, Whitney Goldner, Rebecca E Oberley-Deegan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation and environmental biophysics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. HOxidative medicine and cellular longevity · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Anery PatelDivision of Endocrine, Diabetes and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Elizabeth A KosmacekDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Kurt W FisherDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Whitney GoldnerDivision of Endocrine, Diabetes and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Rebecca E Oberley-DeeganDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA. becky.deegan@unmc.edu.ORCID 0000-0002-0391-142X
University of Nebraska Medical Center · USNebraska Medical Center · US

Funding

Project 9 - Renal Drug Targeting for the Treatment of Lupus NephritisP20GM103480 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2012 to 2017
$13.3M
MnTE-2-PyP as a radioprotector in prostate cancer therapyR01CA178888 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OBERLEY-DEEGAN, REBECCA E · 2014 to 2018
$1.6M
The role of PGC1beta and ERRalpha as novel targets for therapy in colorectal cancerK08CA222887 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FISHER, KURT · 2018 to 2022
$1.2M
NCI NIH HHS K08 CA222887NCI NIH HHS R01 CA178888NIGMS NIH HHS P20 GM103480
6 · The paper itself

Abstract

Treatment of differentiated thyroid cancer often involves administration of radioactive iodine (I-131) for remnant ablation or adjuvant therapy. However, there is morbidity associated with I-131 therapy, which can result in both acute and chronic complications. Currently, there are no approved radioprotectors that can be used in conjunction with I-131 to reduce complications in thyroid cancer therapy. It is well known that the damaging effects of ionizing radiation are mediated, in part, by the formation of reactive oxygen species (ROS). A potent scavenger of ROS, Mn(III)meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin (MnTnBuOE-2-PyP), has radioprotective and anti-tumor effects in various cancer models including head and neck, prostate, and brain tumors exposed to external beam radiation therapy. Female C57BL/6 mice were administered I-131 orally at doses of 0.0085-0.01 mCi/g (3.145 × 10

Indexed as

AnimalsCell Line, TumorFemaleHumansIodine RadioisotopesMetalloporphyrinsMice, Inbred C57BLRadiation-Protective AgentsRadiopharmaceuticalsSalivary GlandsThyroid GlandThyroid NeoplasmsIodine-131Iodine RadioisotopesMetalloporphyrinsMn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrinRadiation-Protective AgentsRadiopharmaceuticalsMnTnBuOE-2-PyPRadioactive iodineRadioprotectorThyroid cancer

Identifiers

PMID31728622
PMCPMC7012978
OpenAlexW2983714580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.